Efficacy and safety of onceweekly semaglutide versus oncedaily sitagliptin as an addon to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56week, doubleblind, phase 3a, randomised trial
Semaglutide and tirzepatide were FDA-approved in 2021 as injectable treatments for weight loss, under the names Wegovy and Mounjaro
Koop uitsluitend via legitieme, gereguleerde kanalen en raadpleeg een arts
Animals are anesthetized with a combination of xylazine (10 mg/kg) and ketamine (90 mg/kg)
doi:10.1097/TP.0b013e31821c1e8b
Who should choose tirzepatide Tirzepatide is the clear winner for anyone who needs substantial weight loss and can access it